Mitsudomi T, Suzuki S, Yatabe Y, Nishio M, Kuwabara M, Gotoh K, Hatooka S, Shinoda M, Suyama M, Ogawa M, Takahashi T, Ariyoshi Y, Takahashi T
Department of Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
J Natl Cancer Inst. 1998 Oct 21;90(20):1563-8. doi: 10.1093/jnci/90.20.1563.
The presence of autoantibodies to p53 protein has been associated with the presence of p53 (also known as TP53) gene mutations in primary tumors and with poor prognosis. This study was undertaken to determine the clinical significance of p53 autoantibodies in patients with non-small-cell lung cancer (NSCLC).
We studied 188 consecutive patients with NSCLC who underwent pulmonary resection and for whom preoperative serum was available. The presence of p53 autoantibodies, detected by use of two amino-terminal and two carboxy-terminal peptides (20-30 mers) as antigens and an enzyme-linked immunosorbent assay, was related to various clinicopathologic parameters and to overexpression of p53 protein in the primary tumor. For 22 patients who had p53 autoantibodies before surgery, we also examined sera taken during postoperative follow-up. Reported P values are two-sided.
Autoantibodies to p53 protein were detected in 38 patients. Patients with squamous cell carcinoma, those with more advanced disease (stage III-IV), and those with tumors that overexpressed p53 had a significantly higher incidence of p53 autoantibodies (P = .05,.0079, and .02, respectively). In all but one of the patients with postoperative serum samples, the antibody titer declined after surgery; however, there was no relationship between clinical course and this change in antibody titer. In addition, there was no relationship between the presence of p53 autoantibodies and overall survival in 171 patients who underwent potentially curative resection (P = .28); however, 13 patients with autoantibodies to amino-terminal peptides had a worse overall survival (P = .02).
In NSCLC, the incidence of p53 autoantibodies is associated with histologic type, stage, and p53 overexpression--but not with patient survival. Our data do not support the clinical utility of p53 autoantibodies as diagnostic or prognostic markers in patients with NSCLC.
p53蛋白自身抗体的存在与原发性肿瘤中p53（也称为TP53）基因突变的存在以及预后不良有关。本研究旨在确定p53自身抗体在非小细胞肺癌（NSCLC）患者中的临床意义。
我们研究了188例连续接受肺切除术且术前有血清样本的NSCLC患者。通过使用两种氨基末端和两种羧基末端肽（20 - 30肽）作为抗原，采用酶联免疫吸附测定法检测p53自身抗体的存在，并将其与各种临床病理参数以及原发性肿瘤中p53蛋白的过表达相关联。对于22例术前有p53自身抗体的患者，我们还检测了术后随访期间采集的血清。报告的P值为双侧。
在38例患者中检测到p53蛋白自身抗体。鳞状细胞癌患者、疾病分期较晚（III - IV期）的患者以及p53过表达肿瘤的患者中p53自身抗体的发生率显著更高（分别为P = 0.05、0.0079和0.02）。在除1例患者外的所有术后有血清样本的患者中，术后抗体滴度下降；然而，临床病程与抗体滴度的这种变化之间没有关联。此外，在171例接受了可能治愈性切除的患者中，p53自身抗体的存在与总生存期之间没有关联（P = 0.28）；然而，13例氨基末端肽自身抗体阳性的患者总生存期较差（P = 0.02）。
在NSCLC中，p53自身抗体的发生率与组织学类型、分期和p53过表达有关，但与患者生存率无关。我们的数据不支持p53自身抗体作为NSCLC患者诊断或预后标志物的临床实用性。
